Figure S7 from Molecular Characterization and Classification of HER2-Positive Breast Cancer Inform Tailored Therapeutic Strategies
Yu-Wei Li(Shanghai Medical College of Fudan University), Zhi‐Ming Shao(Shanghai Medical College of Fudan University), Tong Fu(Fudan University Shanghai Cancer Center), Wentao Yang(Fudan University Shanghai Cancer Center), Yi‐Zhou Jiang(Shanghai Medical College of Fudan University), Xi Jin(First Affiliated Hospital Zhejiang University), Anita Grigoriadis(London Cancer), Ding Ma(Shanghai Medical College of Fudan University), Cai‐Jin Lin(Shanghai Medical College of Fudan University), Shen Zhao(Fudan University Shanghai Cancer Center), Ying Wang(Hebei Medical University), Ming Li, Yu-Zheng Xu(Shanghai Cancer Institute), Yi-Fan Zhou(Shanghai Medical College of Fudan University), Yi Xiao(Fudan University Shanghai Cancer Center), Xiangrong Wu(Shanghai Medical College of Fudan University), Hong Lv(Fudan University Shanghai Cancer Center), Siyuan Chen(King's College London), Lei-Jie Dai(Fudan University Shanghai Cancer Center)
Cited by 0
Related Papers
De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017
|Annals of Oncology|2017|1.3k
BRCA1 Basal-like Breast Cancers Originate from Luminal Epithelial Progenitors and Not from Basal Stem Cells
|Cell stem cell|2010|814
<i>FGFR1</i> Amplification Drives Endocrine Therapy Resistance and Is a Therapeutic Target in Breast Cancer
|Cancer Research|2010|740
Comprehensive metabolomics expands precision medicine for triple-negative breast cancer
|Cell Research|2022|315
The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group
|npj Breast Cancer|2021|282